Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down

Résumé fourni par la source

Extract The introduction of triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) has improved the lives of many people with cystic fibrosis (pwCF) to an unprecedented degree. Yet, 5 years after the introduction of this therapy, studies show that pwCF on ETI will continue to experience residual infection [1–3] and inflammation [4, 5], which are known to be central drivers of disease course. Furthermore, mathematical models of disease trajectories after the introduction of triple CFTR modulator therapy ascertain that age at introduction and thereby severity of lung disease are central determinants of disease trajectories for pwCF on ETI, suggesting that not all pwCF will benefit similarly from these therapies [6].

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.